Abstract
This protocol shows how to reduce immunogenicity by removing CD4+ T cell epitopes. These epitopes may limit the efficacy of protein therapeutics by inducing the development of a long-lived humoral immune response. The approach presented here mainly consists in (i) locate the T cell epitopes by in silico prediction, (ii) design point mutations to eliminate these T cell epitopes, (iii) test the lower immunogenicity of these mutated peptides and (iv) assess the preservation of the three dimensional structure of the antibody as well as its binding affinity for its target.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219–227
Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse human-antibody. Nature 312:643–646
Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351–1361
Chamberlain P (2002) Immunogenicity of therapeutic proteins. Regul Rev 5:4–10
Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR (1989) Conformations of immunoglobulin hypervariable regions. Nature 342:877–883
Foote J, Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224:487–499
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525
Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K (1991) Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 51:5461–5466
Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A (2008) Naive Precursor Frequencies and MHC Binding Rather Than the Degree of Epitope Diversity Shape CD8+ T Cell Immunodominance. J Immunol 181:2124–2133
Liwo A, Czaplewski C, Oldziej S, Scheraga HA (2008) Computational techniques for efficient conformational sampling of proteins. Curr Opin Struct Biol 18:134–139
LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220–4224
Lu M, Dousis AD, Ma J (2008) OPUS-Rota: a fast and accurate method for side-chain modeling. Protein Sci 17:1576–1585
Maloney DG (1999) Preclinical and phase I and II trials of rituximab. Seminars Oncol 26:74–78
Mian IS, Bradwell AR, Olson AJ (1991) Structure, function and properties of antibody binding sites. J Mol Biol 217:133–151
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855
Olson MA, Feig M, Brooks CL 3rd (2008) Prediction of protein loop conformations using multiscale modeling methods with physical energy scoring functions. J Comput Chem 15:820–831
Sivasubramanian A, Sircar A, Chaudhury S, Gray JJ (2009) Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins 74:497–514
Stas P, Pletinckx J, Gansemans Y, Lasters I (2009) Immunogenicity assessment of antibody therapeutics. In: Melvyn L (ed) Recombinant antibodies for immunotherapy. Cambridge University Press, Cambridge
Van Walle I, Gansemans Y, Parren P, Stas P, Lasters I (2007) Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7:405–418
Verhoeyen M, Milstein C, Winter G (1988) Reshaping human antibodies: grafting an antilysozyme activity. Science 239:1534–1536
Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, Damaraju L, Schaible T, Maini RN, Tcheng JE (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112:37–53
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag
About this protocol
Cite this protocol
Alard, P., Desmet, J., Lasters, I. (2010). In Silico De-Immunization. In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01144-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-01144-3_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01143-6
Online ISBN: 978-3-642-01144-3
eBook Packages: Springer Protocols